Enlivex Therapeutics Files 6-K with Financial Updates
Ticker: ENLV · Form: 6-K · Filed: Jun 14, 2024 · CIK: 1596812
Sentiment: neutral
Topics: financial-reporting, 6-K, financial-statements
Related Tickers: ENLV
TL;DR
ENLV dropped Q1 2024 financials in a 6-K filing.
AI Summary
Enlivex Therapeutics Ltd. filed a Form 6-K on June 14, 2024, reporting its unaudited condensed consolidated financial statements for the three-month periods ended March 31, 2024, and March 31, 2023. The filing provides an update on the company's financial performance and operational status as a foreign private issuer.
Why It Matters
This filing provides investors with the latest unaudited financial results for Enlivex Therapeutics, crucial for understanding the company's current financial health and performance trends.
Risk Assessment
Risk Level: low — This is a routine financial filing (6-K) and does not contain new material events or significant financial changes.
Key Players & Entities
- Enlivex Therapeutics Ltd. (company) — Registrant
- March 31, 2024 (date) — Reporting period end
- March 31, 2023 (date) — Reporting period end
- Bioblast Pharma Ltd. (company) — Former company name
FAQ
What is the purpose of this Form 6-K filing?
The purpose of this Form 6-K is to report the unaudited condensed consolidated financial statements for Enlivex Therapeutics Ltd. for the three-month periods ended March 31, 2024, and March 31, 2023.
When was Enlivex Therapeutics Ltd. formerly known as Bioblast Pharma Ltd.?
Enlivex Therapeutics Ltd. was formerly known as Bioblast Pharma Ltd. after a name change on September 19, 2016.
What is the principal executive office address of Enlivex Therapeutics Ltd.?
The principal executive offices of Enlivex Therapeutics Ltd. are located at 14 Einstein Street, Nes Ziona, Israel 7403618.
Does Enlivex Therapeutics Ltd. file annual reports under Form 20-F or Form 40-F?
Enlivex Therapeutics Ltd. files its annual reports under cover of Form 20-F.
What is the SIC code for Enlivex Therapeutics Ltd.?
The Standard Industrial Classification (SIC) code for Enlivex Therapeutics Ltd. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 305 words · 1 min read · ~1 pages · Grade level 9.5 · Accepted 2024-06-14 16:30:24
Filing Documents
- ea0207659-6k_enlivex.htm (6-K) — 11KB
- ea020765901ex99-1_enlivex.htm (EX-99.1) — 231KB
- ea020765901ex99-2_enlivex.htm (EX-99.2) — 72KB
- 0001213900-24-052917.txt ( ) — 316KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Enlivex Therapeutics Ltd. (Registrant) By: /s/ Oren Hershkovitz Name: Title: Oren Hershkovitz Chief Executive Officer Date: June 14, 2024 2